FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005489905> ?p ?o ?g. }

• W2005489905 endingPage "295" @default.
• W2005489905 startingPage "290" @default.
• W2005489905 abstract "Gout affects a large fraction of persons with advanced chronic kidney disease, and hyperuricemia may increase the risk of cardiovascular disease. Several hypouricemic agents are contraindicated in patients with end-stage renal disease. Sevelamer is a nonabsorbed hydrogel that binds phosphorus and bile acids in the intestinal tract. Results of short-term and open-label studies suggest that sevelamer might lower the concentration of uric acid, another organic anion. We undertook this study to test our hypothesis that the reduction in serum uric acid concentration induced by sevelamer would be confirmed in a long-term, randomized, clinical trial comparing sevelamer with calcium-based phosphate binders.Two hundred subjects undergoing maintenance hemodialysis were randomly assigned to receive either sevelamer or calcium-based phosphorus binders in an international, multicenter, clinical trial. Data on baseline and end-of-study uric acid concentrations were available in 169 subjects (85%); the change in uric acid concentration from baseline to the end of the study was the outcome of interest.Baseline clinical characteristics, including mean uric acid concentrations, were similar in subjects randomly assigned to receive sevelamer and calcium-based phosphate binders. The mean change in uric acid concentration (from baseline to the end of the study) was significantly larger in sevelamer-treated subjects (-0.64 mg/dl versus -0.26 mg/dl; P = 0.03). The adjusted mean change in uric acid concentration was more pronounced when the effects of age, sex, diabetes, vintage (time since initiation of dialysis), dialysis dose, and changes in blood urea nitrogen and bicarbonate concentrations were considered (-0.72 mg/dl versus -0.15 mg/dl; P = 0.001). Twenty-three percent of sevelamer-treated subjects experienced a study-related reduction in the concentration of uric acid equal to -1.5 mg/dl or more, compared with 10% of calcium-treated subjects (P = 0.02).In a randomized clinical trial comparing sevelamer and calcium-based phosphate binders, treatment with sevelamer was associated with a significant reduction in serum uric acid concentrations." @default.
• W2005489905 created "2016-06-24" @default.
• W2005489905 creator A5001479828 @default.
• W2005489905 creator A5016072225 @default.
• W2005489905 creator A5021095117 @default.
• W2005489905 creator A5023599600 @default.
• W2005489905 creator A5034939991 @default.
• W2005489905 creator A5054502670 @default.
• W2005489905 creator A5073338334 @default.
• W2005489905 date "2005-01-01" @default.
• W2005489905 modified "2023-10-15" @default.
• W2005489905 title "Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial" @default.
• W2005489905 cites W1977303973 @default.
• W2005489905 cites W1986354946 @default.
• W2005489905 cites W1987332523 @default.
• W2005489905 cites W2013892016 @default.
• W2005489905 cites W2026420466 @default.
• W2005489905 cites W2036551040 @default.
• W2005489905 cites W2037687164 @default.
• W2005489905 cites W2039195112 @default.
• W2005489905 cites W2042564199 @default.
• W2005489905 cites W2045847718 @default.
• W2005489905 cites W2067241022 @default.
• W2005489905 cites W2085717480 @default.
• W2005489905 cites W2106362601 @default.
• W2005489905 cites W2107703251 @default.
• W2005489905 cites W2110693651 @default.
• W2005489905 cites W2113162921 @default.
• W2005489905 cites W2113528337 @default.
• W2005489905 cites W2123238413 @default.
• W2005489905 cites W2133217116 @default.
• W2005489905 cites W2138356436 @default.
• W2005489905 cites W2156442792 @default.
• W2005489905 cites W2318373131 @default.
• W2005489905 cites W2323300482 @default.
• W2005489905 cites W2331027044 @default.
• W2005489905 cites W4323526278 @default.
• W2005489905 doi "https://doi.org/10.1002/art.20781" @default.
• W2005489905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15641045" @default.
• W2005489905 hasPublicationYear "2005" @default.
• W2005489905 type Work @default.
• W2005489905 sameAs 2005489905 @default.
• W2005489905 citedByCount "100" @default.
• W2005489905 countsByYear W20054899052012 @default.
• W2005489905 countsByYear W20054899052013 @default.
• W2005489905 countsByYear W20054899052014 @default.
• W2005489905 countsByYear W20054899052015 @default.
• W2005489905 countsByYear W20054899052016 @default.
• W2005489905 countsByYear W20054899052017 @default.
• W2005489905 countsByYear W20054899052018 @default.
• W2005489905 countsByYear W20054899052019 @default.
• W2005489905 countsByYear W20054899052020 @default.
• W2005489905 countsByYear W20054899052022 @default.
• W2005489905 countsByYear W20054899052023 @default.
• W2005489905 crossrefType "journal-article" @default.
• W2005489905 hasAuthorship W2005489905A5001479828 @default.
• W2005489905 hasAuthorship W2005489905A5016072225 @default.
• W2005489905 hasAuthorship W2005489905A5021095117 @default.
• W2005489905 hasAuthorship W2005489905A5023599600 @default.
• W2005489905 hasAuthorship W2005489905A5034939991 @default.
• W2005489905 hasAuthorship W2005489905A5054502670 @default.
• W2005489905 hasAuthorship W2005489905A5073338334 @default.
• W2005489905 hasBestOaLocation W20054899051 @default.
• W2005489905 hasConcept C126322002 @default.
• W2005489905 hasConcept C126894567 @default.
• W2005489905 hasConcept C134018914 @default.
• W2005489905 hasConcept C2776036575 @default.
• W2005489905 hasConcept C2777425297 @default.
• W2005489905 hasConcept C2778063415 @default.
• W2005489905 hasConcept C2778653478 @default.
• W2005489905 hasConcept C2779148903 @default.
• W2005489905 hasConcept C2779721657 @default.
• W2005489905 hasConcept C2779881121 @default.
• W2005489905 hasConcept C2779978075 @default.
• W2005489905 hasConcept C71924100 @default.
• W2005489905 hasConcept C90924648 @default.
• W2005489905 hasConceptScore W2005489905C126322002 @default.
• W2005489905 hasConceptScore W2005489905C126894567 @default.
• W2005489905 hasConceptScore W2005489905C134018914 @default.
• W2005489905 hasConceptScore W2005489905C2776036575 @default.
• W2005489905 hasConceptScore W2005489905C2777425297 @default.
• W2005489905 hasConceptScore W2005489905C2778063415 @default.
• W2005489905 hasConceptScore W2005489905C2778653478 @default.
• W2005489905 hasConceptScore W2005489905C2779148903 @default.
• W2005489905 hasConceptScore W2005489905C2779721657 @default.
• W2005489905 hasConceptScore W2005489905C2779881121 @default.
• W2005489905 hasConceptScore W2005489905C2779978075 @default.
• W2005489905 hasConceptScore W2005489905C71924100 @default.
• W2005489905 hasConceptScore W2005489905C90924648 @default.
• W2005489905 hasIssue "1" @default.
• W2005489905 hasLocation W20054899051 @default.
• W2005489905 hasLocation W20054899052 @default.
• W2005489905 hasOpenAccess W2005489905 @default.
• W2005489905 hasPrimaryLocation W20054899051 @default.
• W2005489905 hasRelatedWork W1543423153 @default.
• W2005489905 hasRelatedWork W1567135211 @default.
• W2005489905 hasRelatedWork W1966784678 @default.
• W2005489905 hasRelatedWork W1987769635 @default.

• next